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SUMMARY:
Background:
 
Dry cough is a common side-effect of the angiotensin converting enzyme inhibitors (ACEI) and
is a major limiting factor of their use. It has been suggested that ACEI cause this side-effect by potentiation of the
bradykinin effect. Previous work in our laboratory has shown that noscapine, an antitussive drug, inhibits the
effect of bradykinin.
 
Methods:
 
To investigate the effect of noscapine on ACEI-induced cough, 611 hypertensive patients who were
being treated with ACEI were evaluated for the incidence of persistent dry cough.
 
Results:
 
A cough had developed in 65 (10.6%) patients, two (3.1%) of whom also had severe respiratory dis-
tress that required hospitalisation and immediate discontinuation of the ACEI. Forty-two (64.6%) patients had
developed a mild cough and 21 (32.3%) patients had developed a moderate to severe cough. The patients with
moderate to severe cough received 15 mg of noscapine, orally three times daily, while they continued ACEI.
Noscapine effectively resolved the cough in 19 (90%) patients within 4–9 days of starting treatment.
 
Conclusion:
 
Noscapine, possibly by inhibition of bradykinin synthesis, eliminates ACEI-induced cough in the
majority of patients and allows them to continue with ACEI therapy.
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The angiotensin-converting enzyme inhibitors (ACEI) are
among the most widely used medications in patients with
cardiac and renal diseases. While they are generally well tol-
erated, their use has been limited due to their side-effects.
They frequently induce a persistent dry cough, which has
been reported in 5–39% of patients.
 
1–3
 
 In most cases, the
ACEI  has  to  be  discontinued  because  of  this  annoying
side-effect.
 
1
 
The mechanism of ACEI-induced dry cough has been
attributed to bradykinin accumulation and/or the incre-
ment of prostaglandin synthesis associated with the use of
ACEI.
 
4–7
 
 Recent work in our laboratory on the contractile
effects of bradykinin on the guinea pig ileum has shown that
noscapine, an isoquinoline alkaloid found in opium,
 
8
 
 is a
non-competitive inhibitor of this peptide.
 
9
 
 Unlike most
other alkaloids obtained from the opium latex, this drug is
devoid of any significant analgesic, sedative or euphoriant
effects, which are commonly associated with this group of
drugs. The only important and approved clinical effect of
noscapine is its antitussive activity.
 
8
 
 The experimental work
with guinea pigs has shown that noscapine is very effective
as an antitussive agent,
 
10
 
 especially when cough is caused by
bradykinin agonist FR190997 or ACEI, which inhibit the
degradation of bradykinin.
 
11
 
 The present work was carried
out to investigate the effectiveness of noscapine in mitigat-
ing the dry cough induced by ACEI therapy.
 
SUBJECTS AND METHODS
Formulation
 
Noscapine is formulated as compact 15 mg tablets. The direct compac-
tion method is used to prevent any degradation of the drug due to mois-
ture and heat. The main ingredients of the drug are gelatinised starch,
polyvinylpyrrolidone (PVP), avicel, carboxymethyl cellulose (CMC)
and magnesium stearate.
 
Patients and clinical protocol
 
In a period of one year, 611 Iranian hypertensive patients who were
treated with ACEI were evaluated for the incidence of persistent dry
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cough. Sixty-five patients (10.6%) had developed a cough. Among
them, 42 (64.6%) patients had a mild cough, 21 (32.3%) patients had
a moderate to severe cough and two (3.1%) patients had developed
acute respiratory distress that necessitated the patients’ admission to
hospital and prompt discontinuation of the ACEI. We studied the
effect of noscapine in the latter 21 patients, six men and 15 women,
with a mean (
 
±
 
SD) age of 52.7 
 
±
 
 2.2 years. ACEI-induced cough was
defined as a dry cough that occurred after initiation of ACEI therapy,
subsided within 7 days after discontinuation of the drug, and reap-
peared in 48–96 h after restarting the drug. Organic upper respiratory
and pulmonary diseases were ruled out by physical examination and
chest X-rays of the patients before restarting the ACEI. The charac-
teristics of the patients are shown in Table 1. The Ethical Committee/
Institutional Review Board of Rasool Akram Hospital approved the
study and informed consent was obtained from all patients. The study
was performed in the outpatient department of Rasool-Akram-
Hospital, Iran University of Medical Sciences, Tehran, Iran.
 
Medication and evaluation
 
Patients filled a cough diary sheet during the initial 2 weeks of ACEI
therapy. They were asked to score their cough severity according to the
following scale: 0, no cough; 1, only a tickling sensation in the throat;
2, mild cough, which did not interfere with daily activities; 3, moderate
cough, which interrupted some daily activities; and 4, severe cough,
which persisted and interfered with most daily activities and disturbed
sleep at night.
All patients with moderate to severe cough (3–4 score) were
enrolled in the study and received noscapine 15 mg three times daily,
while continuing with ACEI therapy. The dose of noscapine was at its
recommended antitussive dose.
 
12
 
During and after noscapine therapy, patients were asked to fill in a
cough diary in a manner similar to the prenoscapine therapy period and
continued taking noscapine until the severity of the cough was reduced
and/or the cough resolved.
 
Statistical analysis
 
SPSS
 
,  version  11.5,  was  used  for  statistical  analysis.  Paired  Student’s
 
t
 
-test was used for comparison of the cough scores in the pre- and post-
noscapine therapy periods. A 
 
P
 
-value of less than 0.05 was considered
statistically significant.
 
RESULTS
 
The characteristics of the patients who participated in this
study are shown in Table 1. Seventeen (71%) of the
patients were female. The mean (
 
±
 
SD) daily cough score
was 3.8 (
 
±
 
0.09) before noscapine therapy and 0.4 (
 
±
 
0.3) at
the final day of the treatment period, showing a significant
reduction (
 
P
 
 
 
<
 
 0.0001) in the cough score after the nos-
capine therapy. In the majority of patients (90%), a com-
plete response was achieved within 3–10 days of noscapine
therapy. Two of the patients did not respond to noscapine,
which might suggest that an idiosyncratic reaction might
be present in this response. Blood pressures were
maintained around 110–130/70–80 mmHg, pre- and post-
noscapine therapy, and interestingly, four patients required
less antihypertensive medication during noscapine
administration.
 
Table 1
 
Characteristics of patients who were treated with noscapine in the present study
No. Gender Age Diagnosis ACEI Smoker
Cough
severity
No. days to
initial response
No. days to
complete response
1 M 28 GN/HTN Enalapril – 4 3 5
2 M 61 HTN Enalapril
 
+
 
3 2 4
3 F 51 HTN Enalapril – 4 – –
4 F 69 HTN/Hypothy Enalapril – 3 3 5
5 F 44 HTN Enalapril – 4 4 6
6 F 42 HTN Enalapril – 4 3 5
7 F 55 HTN Enalapril – 4 3 5
8 F 41 Hypothy/MGN HTN Enalapril – 4 4 6
9 F 57 HTN Enalapril – 3 3 5
10 F 51 HTN/DN Captopril – 4 – –
11 M 50 DN/HTN Enalapril – 3 3 5
12 F 60 DN/HTN Captopril – 4 4 7
13 F 48 HTN Enalapril – 4 3 5
14 F 54 HTN Enalapril – 4 3 7
15 M 55 DN Captopril – 4 4 7
16 M 71 DN/HTN Captopril – 4 2 4
17 F 50 DN/HTN/CHF Captopril – 4 2 7
18 F 54 DN/HTN Captopril – 4 2 8
19 F 52 DN Enalapril – 4 2 4
20 M 60 HTN Enalapril – 4 2 3
21 F 48 HTN Enalapril – 4 6 10
 
P
 
-value of cough scores between pre- and post-noscapine therapy was statistically significant (
 
P
 
 
 
<
 
 0.0001).
ACEI, angiotensin converting enzyme inhibitor; CHF, congestive heart failure; DN, diabetic nephropathy; F, female; GN, glomerulonephritis;
HTN, hypertension; Hypothy, hypothyroidism; M, male; MGN, membranous glomerulopathy.
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DISCUSSION
 
Dry cough is the most common side-effect associated with
ACEI therapy, and is a major limiting factor in terms of con-
tinuing the medication.
 
1–3
 
 We found an incidence of 10.6%
among the patients in the present study, which is within the
range of 5–39% reported in the literature.
 
1–3
 
 Similar to other
groups, we found that the frequency of cough is higher in
women and non-smokers.
 
13,14
 
 Interestingly, a much higher
incidence of persistent ACEI-induced cough has been
reported in Asians (Chinese patients in Hong Kong), as
compared with Caucasians, 53% versus 18%, respectively,
raising the possibility of racial differences in the susceptibil-
ity to this adverse effect.
 
15
 
Various mechanisms have been implicated in the
pathogenesis of this side-effect. Bradykinin, prostaglan-
dins and nitric oxide (NO) are the most frequently pro-
posed causes of ACEI-induced cough.
 
1–4,16–19
 
 Bradykinin
has both direct and indirect effects on the airways, which
includes bronchoconstriction, bronchodilation, stimula-
tion of cholinergic and sensory nerves, increasing mucous
secretion, inducing cough, and bronchial oedema due to
capillary leakage.
 
17
 
 Nitric oxide is released from cholin-
ergic, sensory and nonadrenergic non-cholinergic nerves.
 
18
 
Bradykinin has three receptors: B1, B2 and B3. The airway
effects are mediated predominantly by the B2 receptor
subtype.
 
19
 
 Several studies have used non-steroidal anti-
inflammatory drugs, such as sulindac and indomethacin, to
abolish this side-effect without any significant benefit.
 
1–5
 
Ebrahimi 
 
et al
 
. showed that FR190976 (a bradykinin ago-
nist) similar to ACEI could potentiate cough reflexes.
 
10
 
The present study shows that noscapine, a bradykinin
antagonist, could effectively suppress cough in patients
treated with ACEI.
 
9
 
 This further supports the involvement
of bradykinin in ACEI-induced cough reflexes. Interest-
ingly, there was no change in blood pressure pre- and post-
noscapine therapy, and four patients required less
antihypertensive medications during noscapine adminis-
tration. This finding was of interest because the antihyper-
tensive effect of ACEI is believed to be at least in part
mediated by bradykinin, which was supposedly blocked by
noscapine. The current results are of interest for patients
who develop this side-effect but need continued therapy
with ACEI for the management of cardiovascular or renal
problems, although angiotensin receptor blockers can
often be safely substituted for ACEI.
Ferrous sulphate has also been shown to reduce ACEI-
induced cough, presumably through inhibition of nitric
oxide synthesis.
 
16
 
 However, while ferrous sulphate therapy
had only reduced the severity of ACEI-induced cough, nos-
capine could eliminate the cough altogether in the vast
majority of patients. However, because cough is a very
subjective symptom and the cough score depended on self-
reporting, the open labelled design of the present study con-
stitutes a weakness that should be resolved in the future by
prospective, randomised, double-blinded studies.
In conclusion, noscapine can be used in the management
of ACEI-induced cough, which would allow continuation of
ACEI therapy. The present findings support the idea that
bradykinin is involved in the induction of cough reflexes
associated with ACEI therapy.
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